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GMP-grade neural progenitor derivation
and differentiation from clinical-grade
human embryonic stem cells
Loriana Vitillo1* , Catherine Durance1, Zoe Hewitt2, Harry Moore2, Austin Smith1,3 and Ludovic Vallier1
Abstract
Background: A major challenge for the clinical use of human pluripotent stem cells is the development of safe,
robust and controlled differentiation protocols. Adaptation of research protocols using reagents designated as
research-only to those which are suitable for clinical use, often referred to as good manufacturing practice (GMP)
reagents, is a crucial and laborious step in the translational pipeline. However, published protocols to assist this
process remain very limited.
Methods: We adapted research-grade protocols for the derivation and differentiation of long-term neuroepithelial
stem cell progenitors (lt-NES) to GMP-grade reagents and factors suitable for clinical applications. We screened the
robustness of the protocol with six clinical-grade hESC lines deposited in the UK Stem Cell Bank.
Results: Here, we present a new GMP-compliant protocol to derive lt-NES, which are multipotent, bankable and
karyotypically stable. This protocol resulted in robust and reproducible differentiation of several clinical-grade
embryonic stem cells from which we derived lt-NES. Furthermore, GMP-derived lt-NES demonstrated a high
neurogenic potential while retaining the ability to be redirected to several neuronal sub-types.
Conclusions: Overall, we report the feasibility of derivation and differentiation of clinical-grade embryonic stem cell
lines into lt-NES under GMP-compliant conditions. Our protocols could be used as a flexible tool to speed up
translation-to-clinic of pluripotent stem cells for a variety of neurological therapies or regenerative medicine studies.
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Background
The stem cell revolution started with the isolation of hu-
man embryonic stem cells (hESCs) [1] followed by the
arrival of induced pluripotent stem cells (iPSCs) [2], and
their differentiation to an ever-increasing number of cell
types has led to the prospect of shifting medicine to a
new paradigm based on cellular repair. Despite this en-
ticing prospect, the number of clinical trials based on
human pluripotent stem cells (hPSCs) remains limited
when compared to other cell types [3]. There is a con-
sensus that hPSCs have a complex and distinct set of
scientific, technical and regulatory bottlenecks that ham-
per their translation to clinical applications [4–7].
One hurdle is that the often-large lists of raw materials
used in differentiation protocols are designated of research-
grade and were never intended for cell therapy applications.
The developers of advanced therapeutic medicinal products
(ATMPs) need to follow strict good manufacturing practice
(GMP) guidelines to ensure quality and safety of the end
products before performing clinical trials. Therefore, raw
materials used in differentiation protocols must meet these
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: l.vitillo@ucl.ac.uk
1Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical
Centre; Department of Surgery, University of Cambridge, Cambridge CB2
0AW, UK
Full list of author information is available at the end of the article
Vitillo et al. Stem Cell Research & Therapy          (2020) 11:406 
https://doi.org/10.1186/s13287-020-01915-0
guidelines. Although policies around raw materials for cell
therapeutics are currently flexible, clinical trials regulations
require for each reagent to be extensively risk-assessed and
qualified [8]. It is in this context that so called GMP-grade
materials suitable for clinical use will facilitate clinical trial
submission and will likely become standard in the field [9].
To comply with such regulations, hESCs have been de-
rived under clinical-grade conditions [10–12] and GMP-
compliant culture platforms have been developed [13,
14]. However, published GMP-compliant differentiation
protocols are still notably lacking, but their development
would significantly speed the translational pipeline for
pluripotent stem cells, particularly for academic groups.
Previous work, including ours, showed that hPSCs could
be differentiated into a long-term neuroepithelial-like
stem cell population, lt-NES, with stable neurogenic po-
tential towards several neuronal sub-types [15, 16]. In the
context of regenerative medicine, a source of neurons that
is expandable, bankable and intermediate (i.e. at progeni-
tor stage) has several advantages over run-through proto-
cols. Lt-NES would reduce processing steps, would be a
convenient quality control check point and could poten-
tially be used for several applications, facilitate scalability
and also by-pass intrinsic line-to-line variability associated
with iPSCs [16]. Here, we develop a novel protocol for the
derivation and differentiation of lt-NES from clinical-
grade hESC lines deposited in the UK Stem Cell Bank
based on GMP-grade media and factors.
Methods
Cell lines and culture methods
Derivation of the MasterShef-3, -4, -7, -8, -10 and -11 cell
lines was performed in the Stem Cell Derivation Facility at
the Centre for Stem Cell Biology, University of Sheffield,
under HFEA licence R0115-8-A (Centre 0191) and HTA
licence 22510, in a clean room setting, following strict
standard operating procedures. The embryos used to de-
rive MasterShef-3, -4, -7, 10 (frozen embryos) and
MasterShef-8 and -11 (fresh embryos) were donated from
different Assisted Conception Units, following fully in-
formed consent, with no financial benefit to the donors,
and were surplus or unsuitable for their IVF treatment.
Briefly, the embryos were cultured using standard IVF cul-
ture media (Medicult), to the blastocyst stage. Following
removal of the trophectoderm using a dissection laser, the
embryos were explanted whole onto either mitotically
inactivated human neonatal fibroblasts (human feeders) in
the case of MasterShef-3, -4, -7, -8 and -10 or onto
Laminin-511 (Biolamina) in the case of MasterShef11.
Derivation media for MasterShef-3, -4, -7 and -8 was
standard KSR/KODMEM (Life Technologies) medium
while MasterShef-10 and -11 were derived in Nutristem
medium (Biological Industries). All cell lines were initially
maintained at 37 °C under 5% O2/ 5% CO2, until the lines
were established, after which maintenance switched 5%
CO2 in air at 37 °C. Cultures were passaged using a man-
ual technique, cutting selected colonies under a dissection
microscope at an average split ratio of 1:2 every 7 days. All
cell lines have been deposited at the UK Stem Cell bank
(https://www.nibsc.org/ukstemcellbank). The H9 cell line
was obtained from the WiCell Institute, USA. lt-NES con-
trol line, here called AF22, was obtained from A. Smith,
Cambridge, UK. AF22 lt-NES were derived from the
hiPSCs line AF22 [16].
HESCs were routinely maintained on recombinant
VTN-N Vitronectin (A14700, Life Technologies), also
tested on the prototype CTS™ (Cell Therapy Systems)
Vitronectin with similar results (now A27940, Life Tech-
nologies), and GMP Essential 8 (A1517001, Life Tech-
nologies). For routine passaging, cells were washed once
with CTS™ DPBS−/− (A1285601, Life Technologies) and
incubated at room temperature for 1–2min with GMP
EDTA (15,575,020, Invitrogen). After aspiration of EDTA,
colonies were gently detached as small clumps and pas-
saged at a ratio of 1:6 without centrifugation. Cells were
frozen in animal-free freezing medium, CryoStem (K1-
0640, Geneflow), and thawed in presence of GMP ROCK
inhibitor Revitacell (1:100, A2644501, Life Technologies).
For traditional research-grade differentiation and re-
agents, refer to the supplemental experimental procedures.
Establishment of GMP lt-NES
Undifferentiated hESCs were dissociated into single cells
with StemPro Accutase (A1110501, Life Technologies) for
2–3min at 37 °C, suspended into GMP Essential 6
(A1516401, Life Technologies), counted with a haemocyt-
ometer and centrifuged at 300×g for 5min. Cells were sus-
pended at a concentration of 3 × 106 into 1.5 ml of (E6)
plus Revitacell, and gently mixed into one well of Aggre-
well 800 (Stem Cell Technologies) previously centrifuged
at 2000×g with 500 μl of E6 plus Revitacell. Embryoid bod-
ies (EBs) formed after 24 h and the media was carefully
and completely replaced with fresh E6. From day 2 till day
4 EBs were fed daily with half media change within the
Aggrewell. At day 5, EBs were detached from the Aggre-
well using a p1000 tip, while a large bore tip (Starlab,
E1011–9618) was used for careful collection and depos-
ition of the EBs on the top of a 37-μm reversible strainer
(Stem Cell Technologies). Multiple cycles were performed
with E6 until all the EBs were removed. EBs were then
plated onto 1 well of a 6-well plate (Corning) coated over-
night with 10 μg/ml of xeno-free human recombinant
Laminin 521 (LN521, Biolamina) prepared in GMP
DPBS+/+ (A1285801, Life Technologies) by reversing the
strainer and washing the EBs into the plate with GMP N2
media (CTS™ DMEM-F12, A1370801; CTS™ N2 1:100,
A1370701; CTS™ B27 1:1000, A1486701; 1% GMP Gluta-
max, A12860-01; Life Technologies). Neural induction
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was induced for 3–5 days by changing GMP N2 media
daily. Neural rosettes were derived between day 3 and 5
by addition of STEMdiff™ Neural Rosette Selection Re-
agent (05832, Stem Cell Technologies) for 45min–1 h at
37 °C. The rosettes were gently detached with N2 media
directed with a p1000 tip on the visible rosette clusters.
Purity of selection was checked under the microscope for
detachment of rosette clusters and non-differentiated
cells. Removed rosettes were collected in a tube and new
media was used to continue selection until 70% of the ro-
settes were collected. Rosettes were centrifuged at 300×g
for 5min and suspended into 400 μl of N2 media plus 10
ng/ml of GMP FGF and GMP EGF (233-GMP-025, 236-
GMP-01M; Bio-techne), named N2 EF media, plus Revi-
tacell. Cells were plated into one to 4 wells of a 48-well
plated pre-coated with 10 μg/ml Laminin 521 avoiding
over pipetting and formation of single cells. For critical
steps and troubleshooting, successful derivation of lt-NES
depends on proper attachment. It is recommended to pre-
pare several laminin plates of various sizes during early
derivation in order to have reserve plates readily available
in the event that attachment is not optimal. A high cell
density is required for lt-NES to survive and proliferate,
around 70%.
Cells were fed daily with GMP N2 EF media. Once
confluent, lt-NES were dissociated with accutase for 1
min at 37 °C, collected by pipetting on the surface and
suspended into 10ml N2 media prior to centrifugation
at 300×g for 5 min. Cells were passaged at a split ratio of
1:1 from a 48-well format to a 6-well plate with addition
of Revitacell for the first 24 h. Once cells were in 6-well
format, Revitacell was not used during passaging and lt-
NES were split at a ratio of 1:2 or 1:3.
GMP lt-NES maintenance
lt-NES were routinely cultured in GMP N2 EF media on
10 μg/ml Laminin 521. Cells were split every 3–4 days
when sub-confluent with incubation with Accutase 1–
2 min at 37 °C (without waiting for the cells to be float-
ing in the media) and suspended into 10 ml N2 media
before centrifugation at 300×g for 5 min. Cells were fro-
zen with CryoStem. lt-NES were thawed at 37 °C for 2
min and immediately resuspended into 10ml N2 media,
centrifuged at 300×g for 5 min and plated in N2 EF
media plus Revitacell for the first 24 h.
Spontaneous differentiation of lt-NES
lt-NES were plated at a density of 40,000 cells/cm2 on Lam-
inin 521-coated plates in N2 media plus Revitacell for 24 h.
The next day, media was changed to terminal differenti-
ation media composed of 50:50 parts of CTS™ DMEM-F12
(with CTS™ N2 1:100) and CTS™ Neurobasal (A1371201,
Life Technologies) (with CTS™ B27 1:50) media plus 300
ng/ml cAMP (Sigma Aldrich). Spontaneous differentiation
was induced with the media above for 21 continuous days.
Directed GMP differentiation into dopaminergic neurons
lt-NES were plated at a density of 40,000 cells/cm2 on
Laminin 521-coated plates in N2 media plus Revitacell
for 24 h. The next day, media was changed to dopamin-
ergic patterning medium composed of CTS™ DMEM-
F12 (with CTS™ N2 1:100) plus freshly added 200 ng/ml
GMP Sonic Hedgehog (SHH, 130-095-727, Miltenyi Bio-
tec), 100 ng/ml GMP FGF-8b (130–095-740, Miltenyi
Biotec) and 160 μM Ascorbic Acid (95210-250G, Sigma
Aldrich). Cells were cultured in dopaminergic patterning
medium for 2 weeks. On day 14, media was changed into
terminal differentiation medium composed of equal
parts of CTS™ DMEM-F12 (CTS™ N2 1:100) to CTS™
Neurobasal (CTS™ B27 1:50) plus 20 ng/ml GMP BDNF
(248-GMP-025, Bio-techne), 10 ng/ml GMP GDNF
(212-GMP-050, Bio-techne), 160 μM Ascorbic Acid
(Sigma Aldrich) and 500 μM dy-cAMP (Sigma Aldrich).
Cells were continuously fed with terminal differentiation
media until day 21, when neurons are ready for im-
munofluorescence characterisation.
Directed GMP differentiation into motoneurons
lt-NES were plated at a density of 40,000 cells/cm2 on
Laminin 521-coated plates in N2 media plus Revitacell for
24 h. The next day, media was changed to motoneuron
patterning medium composed of CTS™ DMEM F12 (With
CTS™ N2 1:100, CTS™ B17 1:50) plus 10 ng/ml GMP EGF
(Bio-techne), 10 ng/ml GMP FGF (Bio-techne) and 1 μM
retinoid acid (Sigma Aldrich). On day 5, the above media
was supplemented with 1 μg/ml GMP SHH (Bio-techne).
From day 7, the concentration of retinoid acid was re-
duced down to 0.01 μM and EGF and FGF were com-
pletely removed. On day 12, media was changed to
terminal differentiation media composed of equal parts of
CTS™ DMEM-F12 (CTS™ N2 1:100) to CTS™ Neurobasal
(CTS™ B27 1:50) plus 20 ng/ml GMP BDNF (Bio-techne),
20 ng/ml GMP GDNF (Bio-techne), 50 ng/ml SHH (Bio-
techne) and 300 ng/ml cAMP (Sigma Aldrich).
Results
Development of an efficient GMP-compatible protocol for
lt-NES derivation
In order to develop a GMP-compatible protocol for lt-
NES derivation, we used H9 hESCs routinely cultured on
a widely recognised and defined culture system based on
recombinant vitronectin and Essential 8 (E8) [13]. We
started by examining the performance of an embryoid
body (EB)-based neural differentiation system under
standard research-grade [16] versus GMP media condi-
tions. HESCs were allowed to aggregate spontaneously in
suspension for 5 days in research-grade knockout serum
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replacement differentiation media (KSR) as previously de-
scribed [16] or in GMP-grade essential 6 (E6), which is
composed similarly to GMP E8 but without bFGF or
TGFβ and thus is suitable for differentiation. The hESCs
formed compacted and round-shaped EBs in KSR, while
in E6 they showed an elevated level of attachment to the
ultra-low adherence dish and disaggregated into smaller
pieces over the 5-day period (Fig. S1A). Consequently, we
observed that poorly formed EBs in E6 were also ineffi-
cient during neural induction, assessed by the hallmark of
neural rosettes, compared to those in KSR (Fig. S1 B).
Moreover, although neural differentiation is clearly pos-
sible via classic spontaneous EB formation methods, this
system is not standardised, as the size and the shape of EBs
is uncontrolled and this impacts on the reproducibility of
differentiation and yield. Therefore, we next examined the
performance of an alternative method to produce EBs of
defined size based on seeding dissociated cells in micro-
wells. HESCs were dissociated into single cells and seeded
at a concentration of 10,000 hESCs per microwell in the
presence of a GMP-grade ROCK inhibitor (Revitacell, Life
Technologies) in either E6 or KSR. After 24 h, similar-sized
EBs were formed in both conditions and at day 5 they
remained aggregated (Fig. 1A and S1 C). Upon dissociation,
an equal number of same-sized EBs was obtained with this
protocol from both KSR and E6 media. We tested the
neural induction efficiency of standardised EBs by looking
for the emergence of neural rosettes after plating in neur-
onal inducing conditions. Surprisingly, neural rosettes
emerged more prevalently from EBs derived from E6 rather
than KSR, in contrast to the spontaneous differentiation
system (Fig. S1 C). Moreover, GMP-neural induction was
robust and highly efficient, as shown by rosettes forming
simultaneously and similarly at the centre of plated EBs
within 3 days (Movie 1). We also tested neural induction
on a defined laminin matrix, laminin 521, now available in
GMP-grade, showing similar results to standard research-
grade poly-L-Ornithine/laminin substrate (Fig. S1 D).
Derivation of lt-NES from neural rosettes has previ-
ously been described using a manual picking system with
needle dissection of rosettes [15, 16]. In the context of
future manufacturing applications for lt-NES, we tested
the suitability of a commercially available rosette selec-
tion solution (STEMdiff™ Neural Rosette Selection, Stem
Fig. 1 Development of an efficient GMP-compatible protocol for lt-NES. a Step-by-step diagram of GMP-compatible differentiation protocol of
hESCs into lt-NES. Scale bars (a, c, d) 100 μm, (b) 50 μm and (e) 20 μm. b Immunofluorescence for lt-NES markers Nestin and Dach1 in research-
grade line H9 after derivation with GMP-compatible protocol. Scale bars 200 μm
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Cell Technologies) with our GMP protocol. Application
of the reagent allowed the pipetting out of loosened
neural rosette cluster from a surrounding non-neural
rosette ring of differentiated cells without the need for
manual dissection (Fig. 1A). With this method, lt-NES
were derived after disaggregating the rosettes and plating
the cells at high density in the presence of GMP-grade
EGF and FGF and cultured thereafter until sub-
confluent. Under these culture conditions, it-NES could
be expanded every 2–3 days, a result of their typical self-
renewing capacity, while maintaining a highly pure
population (Fig. 1A). Indeed, characteristic lt-NES
markers Nestin and Dach1 were expressed homoge-
neously by the cultures differentiated with this protocol
(Fig. 1B).
We concluded that the simultaneous combination of
GMP-grade reagents (Table 1), standardised EB forma-
tion and regent-based rosette isolation provides an effi-
cient system for the derivation of lt-NES using a GMP-
compatible platform.
Neural differentiation potential of clinical-grade hESC lines
With a new GMP-compatible lt-NES derivation protocol
developed, we next examined its robustness by screening
a panel of 6 clinically derived hESC (MasterShef) lines.
MasterShef-3, -4, -7, -8, -10 and -11 were derived at, and
obtained from, the Centre for Stem Cell Biology, Univer-
sity of Sheffield, under a HTA licence for potential clinical
application (22510). With this approach, we aimed to also
examine the specific neural differentiation potential of
these clinical-grade lines which have been deposited in the
UK Stem Cell Bank. Since for the derivation of lt-NES it is
essential to generate neural rosettes, we decided to assess
the differentiation potential based on the ability of the
lines to give rise to morphologically distinct neural ro-
settes. The same number of cells for each line was differ-
entiated into neural rosettes following our protocol and
rosette formation was recorded by imaging the whole cell
culture vessel with high definition imaging using Biosta-
tion CT twice daily for 5 days following EB plating
(Fig. 2a). Four out of six MasterShef lines [4, 7, 8, 11], as
well as an additional hESC research line from a different
source, H9, were able to differentiate into neural rosettes,
showing that the protocol is robust across several different
lines (Fig. 2a). Next, we scored each line for the percent-
age of neural induction by counting the numbers of EBs
hosting neural rosettes in the whole-vessel images at the
end of the induction, normalised to the total number of
EBs attached (Fig. 2b). The efficiency of neural induction
is summarised in Fig. 2c. We defined ‘good’ scores when
more than 50% of the EBs carried rosettes, ‘medium’
scores when the value was below 50% but above 5%, and
null when rosettes were undetected. Good neural induc-
tion scores were obtained regardless of the general level of
spontaneous differentiation in pluripotency maintenance
conditions assessed by daily morphological monitoring of
the cultures for signs of differentiation (Fig. 2c).
Overall, these data demonstrate that our GMP-
compatible protocol is suitable for an efficient neural
differentiation of several clinically relevant hESCs with-
out the need for cell line-specific optimisation.
Establishment and characterisation of GMP-compatible lt-
NES
After screening clinical-grade hESCs with our protocol,
we examined if bona-fide GMP-compatible lt-NES could
be derived and maintained from these lines. We success-
fully established new lt-NES from both a good score,
MasterShef 8 and a medium score line, MasterShef 7,
hESC line, which we named NES8 and NES7, respect-
ively. NES7 and NES8 showed typical lt-NES morph-
ology and self-organised in rosette-like clusters (Fig. 3a),
similarly to the published research-grade lt-NES AF22
(Fig. S2). Furthermore, they homogeneously expressed
lt-NES markers Nestin, SOX2, DACH1, PLZF and the
polarity marker ZO-1 by immunofluorescence (Fig. 3a).
Consistently, NES7 and NES8 also expressed high level
of lt-NES-specific markers by Q-PCR, comparably to
control lt-NES AF22 (Fig. 3b). Our cells also preserved
particularly useful features of lt-NES in the context of
cell therapy manufacturing, such as good recovery after
freeze-thaw (Fig. 3c) and exponential proliferation in
GMP conditions (Fig. 3d) while retaining a rosette-like
morphology (Movie 2). Finally, lt-NES grown on laminin
521 maintained a normal karyotype (results from 30
spreads) after more than 15 passages (Fig. 3e).
These results demonstrate that GMP-compatible lt-
NES derived from clinical-grade hESCs are comparable
to research-grade lt-NES in morphology, markers and
proliferative attributes.
Spontaneous and directed GMP-compatible
differentiation of lt-NES
Lt-NES have been shown to have a spontaneous bias to-
wards hindbrain phenotypes, nevertheless retain multi-
potency and can be directed to differentiate into other
neuronal cell types [15–17]. Therefore, we examined
whether our GMP-compatible lt-NES were able to dif-
ferentiate into neurons in GMP-compatible differenti-
ation conditions, using laminin 521 as substrate.
Firstly, we assessed our lt-NES spontaneous neurogenic
potential by removing growth factors and allowing differ-
entiation in neurogenic GMP media for 21 days by adapt-
ing research-grade protocols [16]. We observed that both
NES7 and NES8 had a high neurogenic potential, giving
rise to a homogenous and interlinked network of neurons
over the course of the differentiation (Movie 3 and Fig. 4).
Indeed, the differentiated lt-NES expressed the neuronal
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marker Beta III tubulin (Fig. 4a). Moreover, we confirmed
the GABAergic propensity of the lt-NES since a large
number of neurons were positive for the GABA marker,
in line with previous reports [18] and similarly to the con-
trol line AF22 (Fig. 4a).
Secondly, we examined the potential of our lt-NES to
be redirected to alternative neuronal types under GMP
differentiation conditions. Substituting reagents from
previous lt-NES research methods [15] with GMP-grade
equivalents, we tested differentiation towards a dopa-
minergic phenotype, which could have interest for cell
transplant studies for Parkinson’s disease. Our results
show that our GMP lt-NES method was able to give rise
to neurons expressing dopaminergic markers tyrosine
hydroxylase (TH) and Nurr1 after 21 days (Fig. 4b).
Finally, lt-NES could also be directed towards a moto-
neuron phenotype in GMP conditions recapitulating
research-grade protocols [15], even if much less
Fig. 2 Neural differentiation potential of clinical grade hESC lines. a Representative phase contrast images of H9 and clinical-grade hESCs
differentiated under GMP-compliant protocol into neural rosettes. Enlarged neural rosettes are visible in the right-hand side panels. Scale bars
200 μm. b Formula for the calculation of neural induction efficiency based on neural rosette in hESC lines. c Summary of screening of research
and clinical-grade hESCs for neural induction capacity under GMP-compatible protocol
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efficiently than for the dopaminergic differentiation, as
showed by detection of the mature motoneuron marker
HB9 by immunofluorescence (Fig. 4c).
In conclusion, our data demonstrated the feasibility of
a fully defined and GMP-compatible protocol for the
derivation and differentiation of hESCs into neurons via
stable and expandable intermediate progenitor lt-NES.
Discussion
In this study, we established a system for the derivation,
maintenance and differentiation of neuroepithelial stem
cells lt-NES under GMP-compliant conditions suitable
for clinical applications. We substituted each reagent of
the original research-grade protocols [15, 16] with avail-
able reagents of sufficient quality standards to allow
their clinical application, so called GMP-approved
reagents or cell therapy-grade reagents. Manufacturers
of such reagents have either lodged ‘drug master files’
with regulatory authorities or are able to provide the de-
tailed quality documentation required to perform a full
risk assessment, which would in turn satisfy an appropri-
ate regulator. In a few circumstances, when such grade
was not readily available, we implemented reagents that
are fully defined or which are in the process of achieving
this standard by the manufacturers.
We also optimised the original differentiation protocol
for transition to cell manufacturing environments. We
found that a controlled and standardised EB formation
was not only desirable but necessary for use of GMP Es-
sential 6 media in the first phase of the protocol. In prac-
tice, this led to higher reproducibility and yield of neural
induction compared to the traditional KSR system. It would
Fig. 3 Establishment and characterisation of GMP-compatible lt-NES. a Representative phase contrast showing morphology of lt-NES derived
from clinical grade MasterShef 7 (NES7) and 8 (NES8). Scale bars 20 μm. NES7 and NES8 cells were immunostained for the lt-NES markers Nestin,
SOX2, Dach1, PLZF and the polarity marker ZO-1. Scale bars 50 μm. b Gene expression levels of lt-NES markers in NES7 and NES8 compared to
research-grade AF22 lt-NES line and assessed by Q-PCR (n = 3). c Recovery after thaw of NES cells at 24 h. Graph shown as mean plus SEM (n = 3).
d Representative growth curve of NES7, NES8 and control AF22 cultured under GMP-compatible conditions on L521. e Normal karyology of
established NES7 at passage 15 cultured in GMP-compatible system
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be interesting to investigate across a greater number of dif-
ferentiation platforms whether the use of GMP-grade re-
agents provides an avenue for improvement of current
research protocols. It would also be interesting to evaluate
whether the choice of routine pluripotency maintenance
conditions affects downstream differentiation.
A critical aspect of hESCs is their intrinsic line-to-line
variability [19]. In the context of cell therapy, our new
protocol demonstrated robustness when applied to six dif-
ferent clinical-grade hESC lines with a 66.6% efficiency.
Moreover, lt-NES derived from hESCs with different
neural differentiation propensities expressed similar char-
acterisation attributes between each other and to a control
research-grade line. These findings confirm previous data
reporting that lt-NES derivation may circumvent up-
stream differences between hPSC lines [16], but here also
showing comparability across different derivation condi-
tions (i.e. GMP vs research protocol). Indeed, our control
NES line used throughout this study, AF22 [16], not only
was derived under research-grade protocols but also from
a human iPSC line. The ability of hiPSC-derived AF22 to
be expanded and terminally differentiated with our GMP
protocol in parallel to hESCs-derived lt-NES suggest that
the protocol is applicable to both hESC and iPSC-derived
lt-NES. Nonetheless, it would be important to test the en-
tire GMP derivation on a set of clinical-grade hiPSCs as
Fig. 4 Spontaneous and directed GMP-compatible differentiation of lt-NES. a Spontaneous differentiation of NES lines into neurons under GMP-
compatible conditions. Spontaneous neurogenic potential shown by phase contrast (scale bars 100 μm) and immunostaining for neuronal marker BIII
Tubulin (NES7; scale bar 400 μm). Typical hindbrain bias of lt-NES shown by expression of GABAergic markers GABA (scale bars 400 μm). b Directed
differentiation of NES lines into midbrain dopaminergic neurons under GMP-compatible conditions. Immunostaining images showing positivity for
dopaminergic markers tyrosine hydroxylase (TH) and Nurr1. Scale bars 400 μm (200 μm for AF22 Nurr1). c Directed differentiation of NES lines into
motoneurons under GMP-compatible conditions showing motor neuron marker HB9 expression by immunofluorescence. Scale bars 100 μm
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they will become increasingly available to the cell therapy
community. As expected, a few of the screened lines were
not able to differentiate efficiently under this protocol,
reflecting the known characteristic of hESC lines to have
different developmental potentials. In this regard, this
study strengthens the view that screening a panel of pluri-
potent lines is crucial for cell therapy applications.
We also established that GMP-grade maintenance con-
ditions support the features of self-renewing lt-NES:
rosette-like morphology, homogeneous and stable expres-
sion of neural rosettes markers, long-term expansion in
EGF/FGF, resistance to repeated freeze/thawing and stable
karyotype. Moreover, our lt-NES displayed high neuro-
genic potential towards GABAergic sub-types upon
growth factors removal, in line with their hindbrain iden-
tity [15, 16]. lt-NES could be successfully re-specified to-
wards adjacent regional cell types such as dopaminergic
neurons and to a less degree also to motor neurons under
GMP-culture conditions, confirming their multipotential-
ity. Therefore, with these protocols, we intend to offer a
flexible starting point and cut the burden of time-
consuming and expensive process development.
The clinical future of pluripotent stem cell-derived
therapeutics will likely depend on our ability to tackle
several roadblocks associated with the development of
cell manufacturing processes, of which adaptation to
suitable qualified materials is a crucial phase [4–7]. This
study shows that translation of research-grade protocols
to GMP-compliant protocols can be effectively achieved
and that making these changes can lead to robust and
efficient processes. Stem cell researchers looking at tran-
sitioning to clinic can take our results as positive evi-
dence that the original research protocol blueprint can
be maintained and built upon. However, the time and
cost commitment to achieving this should not be under-
estimated, and with few reports in the literature to docu-
ment these processes, many developers have to start
from the beginning.
Conclusion
Overall, the findings of the present report demonstrate
feasibility of a GMP-compliant differentiation protocol
for intermediate neural progenitors that are easy to ex-
pand, bankable and amenable to downstream differenti-
ation into different neuronal sub-types. In the context of
the cell therapy field, we report pre-screening of the
neuronal differentiation capacity of 6 clinical-grade Mas-
terShef hESC lines deposited in the UK Stem Cell Bank
and established a resource in GMP lt-NES that could be
used for further optimization depending on the required
therapeutic goal. Recently, a method for differentiating
lt-NES towards astroglia has been developed, opening
new avenues for the downstream therapeutic use of
GMP lt-NES [17]. Considering the promising
comparability between our GMP lt-NES and the AF22
lt-NES also used by Lundin et al. [17], it would be inter-
esting to test the performance of our GMP lt-NES to-
wards astroglia in future studies. Given its robustness
and flexibility, our protocol could be applied for the gen-
eration of GMP-compliant neural progenitors that are
potentially employable for a variety of neurological ther-
apies, for cell manufacturing scalability studies, drug
screenings and other biomedical research applications
[20].
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